GlassScriptPhysician profile
Isabel C Guerrero
NPI 1568456580
$2,768.79
in general payments reported to CMS, 2019-2025
17 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $122 · 2021: $465 · 2022: $355 · 2023: $475 · 2024: $378 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.23 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $736.90 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $660.39 | 2021-2025 | |
| Gilead Sciences, INC. | $520.69 | 2019-2023 | Epclusa |
| Astellas Pharma US INC | $209.98 | 2019-2024 | |
| Allergan, INC. | $165.25 | 2019-2020 | |
| Theratechnologies INC. | $135.61 | 2023-2025 | Egrifta Sv, Trogarzo, Egrifta |
| Viiv Healthcare Company | $86.81 | 2021 | |
| Paratek Pharmaceuticals, INC. | $79.94 | 2019-2020 | |
| Sanofi Pasteur INC. | $34.50 | 2020 | |
| Shionogi INC | $33.61 | 2025 | Fetroja |
| Biomerieux INC | $26.66 | 2021 | |
| Portola Pharmaceuticals, LLC | $14.87 | 2019 | |
| Boston Scientific Corporation | $14.00 | 2019 | |
| Pfizer INC. | $13.74 | 2025 | |
| Aimmune Therapeutics, INC. | $12.79 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $11.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.